Is Nonmicronized Diosmin 600 mg as Effective as Micronized Diosmin 900 mg plus Hesperidin 100 mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study
Table 1
Characteristics of patients at baseline (per-protocol population).
Characteristics
D-group
D/H-group
Total
Age (years), mean (SD)
43.2 (11.2)
45.6 (10.3)
44.4 (10.8)
Female gender, (%)
52 (91.2)
51 (89.5)
103 (90.4)
Ethnicity, (%)
Asian
1 (1.8)
0
1 (0.9)
Caucasian
32 (56.1)
27 (47.4)
59 (51.8)
Black
9 (15.8)
9 (15.8)
18 (15.8)
Brown
15 (26.3)
21 (36.8)
36 (31.6)
Body mass index (kg/m2), mean (SD)
25.7 (3.4)
26.0 (3.6)
25.9 (3.5)
Reference leg, (%)
Right
23 (40.4)
33 (57.9)
56 (49.1)
Left
34 (59.6)
24 (42.1)
58 (50.9)
CEAP classification, (%)
C0a
0
1 (1.8)
1 (0.9)
C1
21 (36.8)
20 (35.1)
41 (36.0)
C2
25 (43.9)
21 (36.8)
46 (40.4)
C3
11 (19.3)
15 (26.3)
26 (22.8)
Medical history, (%)
Ear, nose, and throat
7 (12.3)
3 (5.3)
10 (8.8)
Cardiopulmonary
7 (12.3)
10 (17.5)
17 (14.9)
Digestive system
10 (17.5)
6 (10.5)
16 (14.0)
Nervous system
4 (7.0)
7 (12.3)
11 (9.6)
Musculoskeletal system
3 (5.3)
3 (5.3)
6 (5.3)
Skin
7 (12.3)
6 (10.5)
13 (11.4)
Others
3 (5.3)
8 (14.0)
11 (9.6)
Venous symptoms (VAS) (mm)
47.1 (8.2)
50.3 (9.5)
48.7 (9.0)
VAS: visual analog scale; S: symptomatic. aThe patient rated C0 was symptomatic.
